建議您使用以下瀏覽器觀看本網站,
以獲得最佳瀏覽效果。
![](../images/about/about.jpg)
TheratOcular Biotek, a clinical-stage biotechnology company, is exclusively focusing on development of user-friendly and cost-effective treatments for diseases and conditions of the eye.
View MoreOUR PRODUCTS
![TO-O-1001](../images/product/pdt01.png?new)
TO-O-1001
TO-O-1001 for POAG and OH
A patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension.
![TO-O-1002](../images/product/pdt01.png?new)
TO-O-1002
Wet AMD
The first “Eye Drops” formulation ever be brought into wet AMD market for patients’ ease of use and overall therapeutic benefit.
![TO-O-1003](../images/product/pdt01.png?new)
TO-O-1003
TO-O-1003 for Dry eye
The unique dual action pathway (promoting tear secretion and anti-inflammatory response) can effectively reduce the discomfort of dry eye patients.
![TO-O-1004](../images/product/pdt01.png?new)
TO-O-1004
TO-O-1004 for Post-Operative Pain and Inflammation with Cataract Surgery
Aiming to treat the post-operative inflammation and improve the quality of life after surgery.
![TO-O-1005](../images/product/pdt01.png?new)
TO-O-1005
TO-O-1005 for Presbyopia
Aiming to restore accommodation ability of lens for Presbyopia patients.
![TO-O-1006](../images/product/pdt01.png?new)
TO-O-1006
TO-O-1006 for Dry AMD
Special formulation to assist the elimination of drusen, and delay dryAMD progression.
LASTEST NEWS
![](../images/news/news12.jpg)
TO-O-1001 & TO-O-1002 won the 2023 R&D 100 Award
![](../images/news/news11.jpg)
MG-O-1002 (TO-O-1002) project won the 2023 Edison Awards™
![](../images/news/news10.jpg)
ITRI Special Issue ----
Interview with Dr. Sean Chen, chairman of TheratOcular Biotek
![](../images/news/news09.jpg)
New blue ocean for ophthalmology drugs; Taiwanese manufacturers are actively improving innovative technologies
![](../images/news/news08.jpg)
Old formula New amazing effect, TheratOcular Biotek makes it easy to treat eye diseases - Executive VP Simon Huang Interview
![](../images/news/news07.jpg)
63th Annual Meeting of Ophthalmology & 15th Asia Pacific Vitreoretinal Society (APVRS) Congress
![](../images/news/news06.jpg)
Press conference of innovative eye drops
![](../images/news/news05.jpg)
TO-O-1002 Investigator meeting (IM) in Thailand
![](../images/news/news00.jpg)
The phase II clinical trial of TO-O-1002 approved by the Central Research Ethics Committee (CREC) in Thailand on 11 Aug 2022.
![](../images/news/news00.jpg)
The phase I/II clinical trials of TO-O-1001 approved by the Australian Human Research Ethics Committee (HREC) on 4 Aug 2022.
![](../images/news/news02.jpg)
The company Chair, Dr. Sean Chen, and the SAB Chair, Dr. Lu Da-Wen, get together with all the honorary members of the Company Scientific Advisory Borad (SAB) in a banquet.
![](../images/news/news01.jpg)